Liposome of foxo1 inhibitor as1842856, and preparation method and application thereof

By designing the AS1842856 liposome nanotherapy system, the problem of low water solubility of AS1842856 was solved, enabling targeted treatment of fibrotic sites, reducing inflammatory cell infiltration and extracellular matrix deposition, and providing an effective fibrosis treatment solution.

CN122140627APending Publication Date: 2026-06-05PEKING UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Applications(China)
Current Assignee / Owner
PEKING UNIV
Filing Date
2025-12-01
Publication Date
2026-06-05

AI Technical Summary

Technical Problem

The existing FOXO1 selective inhibitor AS1842856 has extremely low water solubility, which limits its drug development and efficacy in clinical applications. Furthermore, there are no reports on the use of liposomal formulations for the prevention and treatment of fibrotic diseases.

Method used

A liposome-based nanotherapy system for AS1842856 was designed. By encapsulating AS1842856 in liposomes, the system targets macrophages in the fibrosis process. The liposome-based drug delivery system enhances drug solubility and targeting, regulates drug release, and has a simple preparation method and definite efficacy.

Benefits of technology

It effectively reduces inflammatory cell infiltration at fibrotic sites, increases the number of parenchymal cells, reduces extracellular matrix deposition, significantly improves fibrotic lesions, and provides a high-end formulation for the clinical treatment of fibrotic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The application discloses a liposome of a FOXO1 inhibitor AS1842856 and a preparation method and application thereof. The liposome comprises the following raw materials: phospholipid, cholesterol, phospholipid PEG derivative and AS1842856; wherein the proportion of the phospholipid, the cholesterol and the phospholipid PEG derivative (for example, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 (DSPE-PEG2000)) is preferably in the range of 10:0.2-2:0.5-5 (w / w); wherein the AS1842856 is wrapped in the liposome. The AS1842856 liposome of the application has excellent physical and chemical properties and has a wide application prospect in the field of fibrosis disease treatment.
Need to check novelty before this filing date? Find Prior Art